Epidemiology of lung cancer: Looking to the future

Journal of Clinical Oncology

Volumn 23, Issue 14, 2005, Pages 3175-3185

  Alberg, Anthony J ^a   Brock, Malcolm V ^a   Samet, Jonathan M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; ASBESTOS; BIOLOGICAL MARKER; CHROMIUM; NICKEL; RADON;

CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CIGARETTE SMOKING; DIET; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; EPIDEMIC; ETHNICITY; GENDER; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LUNG CANCER; OCCUPATIONAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SOCIOECONOMICS; SQUAMOUS CELL CARCINOMA; UNITED STATES; WORKPLACE; HEALTH; LUNG TUMOR; MORTALITY; SMOKING;

HUMANS; LUNG NEOPLASMS; MORTALITY; PREVALENCE; RISK FACTORS; SMOKING; UNITED STATES; WORLD HEALTH;

EID: 19844373387     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.462     Document Type: Review

References (125)

1. US Department of Health Education and Welfare: Smoking and health. Report of the Advisory Committee to the Surgeon General. DHEW Publication No. [PHS] 1103. Washington, DC, U.S. Government Printing Office, 1964
2. US Department of Health and Human Services: The health effects of active smoking: A report of the Surgeon General. Washington, DC, U.S. Government Printing Office, 2004
3. Proctor RN: The Nazi War on Cancer. Princeton, NJ, Princeton University Press, 1999
4. Wynder EL, Graham EA: Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of six hundred and eighty-four proved cases. J Am Med Assoc 143:329-36, 1950
5. Levin ML, Goldstein H, Gerhardt PR: Cancer and tobacco smoking; a preliminary report. J Am Med Assoc 143:336-338, 1950
6. Doll R, Hill AB: Smoking and carcinoma of the lung; a preliminary report. Br Med J 2:739-748, 1950
7. Doll R, Hill AB: The mortality of doctors in relation to their smoking habits; a preliminary report. Br Med J 1:1451-1455, 1954
8. Burney LE: Excessive cigarette smoking. Public Health Rep 72:786, 1957
9. Burney LE: Smoking and lung cancer. A statement of the public health service. JAMA 171:1829-1836, 1959
10. Cornfield J, Haenszel W, Hammond EC, et al: Smoking and lung cancer: Recent evidence and a discussion of some questions. J Natl Cancer Inst 22:173-203, 1959
11. Hirayama T: Non-smoking wives of heavy smokers have a higher risk of lung cancer: A study from Japan. Br Med J (Clin Res Ed) 282:183-185, 1981
12. Trichopoulos D, Kalandidi A, Sparros L, et al: Lung cancer and passive smoking. Int J Cancer 27:1-4, 1981
13. Price B, Ware A: Mesothelioma trends in the United States: An update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 159:107-112, 2004
14. Pisani P, Parkin DM, Bray F, et al: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18-29, 1999
15. Blot WJ, Fraumeni JF Jr: Cancers of the lung and pleura, in Schottenfeld D, Fraumeni JF Jr (eds): Cancer Epidemiology and Prevention. New York, Oxford University Press, 1996, pp 637-665
16. Alberg AJ, Samet JM: Epidemiology of lung cancer. Chest 123:21S-49S, 2003
17. International Agency for Research on Cancer: Tobacco smoke and involuntary smoking. IARC monograph 83. Lyon, France, International Agency for Research on Cancer, 2004
18. Churg A: Lung cancer cell type and occupational exposure, in Samet JM (ed): Epidemiology of Lung Cancer. New York, Marcel Dekker, 1994, pp 413-436
19. Khuder SA: Effect of cigarette smoking on major histological types of lung cancer: A meta-analysis. Lung Cancer 31:139-148, 2001
20. National Research Council: Committee on Health Risks of Exposure to Radon, Board on Radiation Effects Research, and Commission on Life Sciences. Health Effects of Exposure to Radon (BEIR VI). Washington, DC, National Academy Press, 1998
21. Vincent RG, Pickren JW, Lane WW, et al: The changing histopathology of lung cancer: A review of 1682 cases. Cancer 39:1647-1655, 1977
22. Charloux A, Quoix E, Wolkove N, et al: The increasing incidence of lung adenocarcinoma: Reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 26:14-23, 1997
23. Hecht SS: Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 91:1194-1210, 1999
24. US Department of Health and Human Services: Women and smoking. A report of the Surgeon General. Rockville, MD, US Department of Health and Human Services, 2001
25. Thun MJ, Lally CA, Flannery JT, et al: Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 89: 1580-1586, 1997
26. National Cancer Institute: The FTC cigarette test method for determining tar, nicotine, and carbon monoxide yields of US cigarettes. Bethesda, MD, National Institutes of Health, 1996
27. Wynder EL, Muscat JE: The changing epidemiology of smoking and lung cancer histology. Environ Health Perspect 103:143-148, 1995 (suppl 8)
28. Hoffmann D, Hoffmann I: The changing cigarette, 1950-1995. J Toxicol Environ Health 50:307-364, 1997
29. US Department of Health and Human Services; National Cancer Institute: Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Bethesda, MD, National Institutes of Health, 2001
30. Thun MJ, Day-Lally C, Myers DG, et al: Trends in tobacco smoking and mortality from cigarette use in Cancer Prevention Studies I (1959-1965) and II (1982-1988), in Burns DM, Garfinkel L, Samet JM (eds): Changes in Cigarette Related Disease Risks and Their Implication for Prevention and Control. Bethesda, MD, National Cancer Institute, 1997, pp 305-382
31. Institute of Medicine: The unequal burden of cancer: An assessment of NIH research and programs for ethnic minorities and the medically underserved. Washington, DC, National Academies Press, 1999
32. National Cancer Institute: Cancer rates and risks. National Cancer Institute, Bethesda, MD, 2004
33. US Cancer Statistics Working Group: United States cancer statistics: 2001 incidence and mortality. Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute, 2004
34. Hebert JR: Invited commentary: Menthol cigarettes and risk of lung cancer. Am J Epidemiol 158:617-620, 2003
35. Giovino GA, Sidney S, Gfroerer JC, et al: Epidemiology of menthol cigarette use. Nicotine Tob Res 6:S67-S81, 2004 (suppl 1)
36. Ahijevych K, Garrett BE: Menthol pharmacology and its potential impact on cigarette smoking behavior. Nicotine Tob Res 6:S17-S28, 2004 (suppl 1)
37. Brooks DR, Palmer JR, Strom BL, et al: Menthol cigarettes and risk of lung cancer. Am J Epidemiol 158:609-616, 2003
38. Carpenter CL, Jarvik ME, Morgenstern H, et al: Mentholated cigarette smoking and lung-cancer risk. Ann Epidemiol 9:114-120, 1999
39. Sidney S, Tekawa IS, Friedman GD, et al: Mentholated cigarette use and lung cancer. Arch Intern Med 155:727-732, 1995
40. Kabat GC, Hebert JR: Use of mentholated cigarettes and lung cancer risk. Cancer Res 51:6510-6513, 1991
41. Mao Y, Hu J, Ugnat AM, et al: Socioeconomic status and lung cancer risk in Canada. Int J Epidemiol 30:809-817, 2001
42. Li K, Yu S: Economic status, smoking, occupational exposure to rubber, and lung cancer: A case-cohort study. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 20:21-28, 2002
43. van Loon AJ, Goldbohm RA, Kant IJ, et al: Socioeconomic status and lung cancer incidence in men in The Netherlands: Is there a role for occupational exposure? J Epidemiol Community Health 51:24-29, 1997
44. Schwartz KL, Crossley-May H, Vigneau FD, et al: Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control 14:761-766, 2003
45. US Department of Health and Human Services: The health consequences of smoking for women: A report of the surgeon general. US Department of Health and Human Services, Public Health Service, Office of the Assistant Secretary for Health, Office of Smoking and Health, 1980
46. Risch HA, Howe GR, Jain M, et al: Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 138:281-293, 1993
47. Zang EA, Wynder EL: Differences in lung cancer risk between men and women: Examination of the evidence. J Natl Cancer Inst 88: 183-192, 1996
48. Etter J-F, Perneger TV, Ronchi A: Distributions of smokers by stage: International comparison and association with smoking prevalence. Prev Med 26:580-585, 1997
49. Bain C, Feskanich D, Speizer FE, et al: Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 96:826-834, 2004
50. Jemal A, Travis WD, Tarone RE, et al: Lung cancer rates convergence in young men and women in the United States: Analysis by birth cohort and histologic type. Int J Cancer 105:101-107, 2003
51. Bjelke E: Dietary vitamin A and human lung cancer. Int J Cancer 15:561-565, 1975
52. Peto R, Doll R, Buckley JD, et al: Can dietary beta-carotene materially reduce human cancer rates? Nature 290:201-208, 1981
53. Alberg AJ, Samet JM: Epidemiology of lung cancer, in Sadler MJ, Caballero B, Strain JJ (eds): Encyclopedia of Human Nutrition. London, Academic Press, 1998, pp 235-248
54. Wright ME, Mayne ST, Swanson CA, et al: Dietary carotenoids, vegetables, and lung cancer risk in women: The Missouri Women's Health study (United States). Cancer Causes Control 14:85-96, 2003
55. Skuladottir H, Tjoenneland A, Overvad K, et al: Does insufficient adjustment for smoking explain the preventive effects of fruit and vegetables on lung cancer? Lung Cancer 45:1-10, 2004
56. Neuhouser ML, Patterson RE, Thornquist MD, et al: Fruits and vegetables are associated with lower lung cancer risk only in the placebo arm of the beta-carotene and retinol efficacy trial (CARET). Cancer Epidemiol Biomarkers Prev 12: 350-358, 2003
57. Holick CN, Michaud DS, Stolzenberg-Solomon R, et al: Dietary carotenoids, serum beta-carotene, and retinol and risk of lung cancer in the alpha-tocopherol, beta-carotene cohort study. Am J Epidemiol 156:536-547, 2002
58. Feskanich D, Ziegler RG, Michaud DS, et al: Prospective study of fruit and vegetable consumption and risk of lung cancer among men and women. J Natl Cancer Inst 92:1812-1823, 2000
59. Miller AB, Altenburg HP, Bueno-de-Mesquita B, et al: Fruits and vegetables and lung cancer: Findings from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 108:269-276, 2004
60. Mannisto S, Smith-Warner SA, Spiegelman D, et al: Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. Cancer Epidemiol Biomarkers Prev 13:40-48, 2004
61. Le Marchand L, Murphy SP, Hankin JH, et al: Intake of flavonoids and lung cancer. J Natl Cancer Inst 92:154-160, 2000
62. Knekt P, Jarvinsn R, Seppanen R, et al: Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol 146:223-230, 1997
63. Zhao B, Seow A, Lee EJ, et al: Dietary isothiocyanates, glutathione S-transferase -M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore. Cancer Epidemiol Biomarkers Prev 10:1063-1067, 2001
64. Spitz MR, Duphorne CM, Detry MA, et al: Dietary intake of isothiocyanates: Evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk. Cancer Epidemiol Biomarkers Prev 9:1017-1020, 2000
65. London SJ, Yuan JM, Chung FL, et al: Isothiocyanates, glutathione S-transferase M1 and T1 polymorphisms, and lung-cancer risk: A prospective study of men in Shanghai, China. Lancet 356:724-729, 2000
66. Korte JE, Brennan P, Henley SJ, et al: Dose-specific meta-analysis and sensitivity analysis of the relation between alcohol consumption and lung cancer risk. Am J Epidemiol 155: 496-506, 2002
67. Knekt P, Heliovaara M, Rissanen A, et al: Leanness and lung cancer risk. Int J Cancer 49:208-213, 1991
68. Olson JE, Yang P, Schmitz K, et al: Differential association of body mass index and fat distribution with three major histologic types of lung cancer: Evidence from a cohort of older women. Am J Epidemiol 156:606-615, 2002
69. Saccomanno G, Archer VE, Auerbach O, et al: Development of carcinoma of the lung as reflected in exfoliated cells. Cancer 33:256-270, 1974
70. Travis WD: Pathology of lung cancer. Clin Chest Med 23:65-81, 2002
71. Wistuba II, Behrens C, Virmani AK, et al: Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 59:1973-1979, 1999
72. Belinsky SA, Palmisano WA, Gilliland FD, et al: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62:2370-2377, 2002
73. Brauch H, Johnson B, Hovis J, et al: Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. N Engl J Med 317:1109-1113, 1987
74. Kok K, Osinga J, Carritt B, et al: Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330:578-581, 1987
75. Johnson BE, Sakaguchi AY, Gazdar AF, et al: Restriction fragment length polymorphism studies show consistent loss of chromosome 3p alleles in small cell lung cancer patients' tumors. J Clin Invest 82:502-507, 1988
76. Naylor SL, Johnson BE, Minna JD, et al: Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329:451-454, 1987
77. Sozzi G, Veronese ML, Negrini M, et al: The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85:17-26, 1996
78. Tomizawa Y, Iijima H, Nomoto T, et al: Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer. Lung Cancer 46:305-312, 2004
79. Kim DH, Kim JS, Ji YI, et al: Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 63:3743-3746, 2003
80. Marsit CJ, Kim DH, Liu M, et al: Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: Implications for tobacco smoking during adolescence. Int J Cancer 114:219-223, 2005
81. Hirao T, Nelson HH, Ashok TD, et al: Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. Cancer Res 61:612-615, 2001
82. Nelson HH, Wiencke JK, Gunn L, et al: Chromosome 3p14 alterations in lung cancer: Evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res 58:1804-1807, 1998
83. Zienolddiny S, Ryberg D, Arab MO, et al: Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br J Cancer 84:226-231, 2001
84. Swafford DS, Middleton SK, Palmisano WA, et al: Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol Cell Biol 17:1366-1374, 1997
85. ink4a is an early event in lunch cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 95:11891-11896, 1998
86. Destro A, Bianchi P, Alloisio M, et al: K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 44:23-32, 2004
87. Toyooka S, Suzuki M, Tsuda T, et al: Dose effect of smoking on aberrant methylation in non-small cell lung cancers. Int J Cancer 110: 462-464, 2004
88. Rodenhuis S, Slebos RJ: Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52:2665s-2669s, 1992
89. Slebos RJ, Hruban RH, Dalesio O, et al: Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 83:1024-1027, 1991
90. Slebos RJ, Kibbelaar RE, Dalesio O, et al: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323:561-565, 1990
91. D'Amico D, Carbone D, Mitsudomi T, et al: High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 7:339-346, 1992
92. Chiba I, Takahashi T, Nau MM, et al: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene 5:1603-1610, 1990
93. Symonds H, Krall L, Remington L, et al: p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711, 1994
94. Vogelstein B, Kinzler KW: Achilles' heel of cancer? Nature 412:865-866, 2001
95. Schrump DS, Roth JA: Molecular biology and immunology of lung and esophageal cancer, in Baue AE, Geha AS, Hammond GL, (eds): Glenn's thoracic and cardiovascular surgery. Stamford, CT, Appleton & Lange, 1996, pp 331-341
96. Wiencke JK, Nelson H, Wain J, et al: Association of increased PAH DNA adducts and p53 mutations in lung cancer. Proc Am Assoc Cancer Res 39:562, 1998 (abstr 3821)
97. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-ceil lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237-2246, 2003
98. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
99. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
100. Huang SF, Liu HP, Li LH, et al: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 10:8195-8203, 2004
101. Mattson ME, Pollack ES, Cullen JW: What are the odds that smoking will kill you? Am J Public Health 77:425-431, 1987
102. Garte S, Zocchetti C, Taioli E: Gene-environment interactions in the application of biomarkers of cancer susceptibility in epidemiology. IARC Sci Publ:251-264, 1997
103. Vineis P, Veglia F, Benhamou S, et al: CYP1A1 T3801 C polymorphism and lung cancer: A pooled analysis of 2451 cases and 3358 controls. Int J Cancer 104:650-657, 2003
104. Le Marchand L, Guo C, Benhamou S, et al: Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). Cancer Causes Control 14:339-346, 2003
105. Economou P, Lechner JF, Samet JM: Familial and genetic factors in the pathogenesis of lung cancer, in Samet JM (ed): Epidemiology of Lung Cancer. New York, NY, Marcel Dekker, 1994, pp 353-396
106. Amos CI, Caporaso NE, Weston A: Host factors in lung cancer risk: A review of interdisciplinary studies. Cancer Epidemiol Biomarkers Prev 1:505-513, 1992
107. Shaw GL, Falk RT, Deslauriers J, et al: Debrisoquine metabolism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 4:41-48, 1995
108. Christensen PM, Gotzsche PC, Brosen K: The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: A meta-analysis. Eur J Clin Pharmacol 51:389-393, 1997
109. Rostami-Hodjegan A, Lennard MS, Woods HF, et al: Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics 8:227-238, 1998
110. Benhamou S, Lee WJ, Alexandrie AK, et al: Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis 23:1343-1350, 2002
111. Hung RJ, Boffetta P, Brockmoller J, et al: CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: A pooled analysis. Carcinogenesis 24:875-882, 2003
112. Berwick M, Vineis P: Markers of DNA repair and susceptibility to cancer in humans: An epidemiologic review. J Natl Cancer Inst 92:874-897, 2000
113. Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11:1513-1530, 2002
114. Spitz MR, Wei Q, Dong Q, et al: Genetic susceptibility to lung cancer: The role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 12:689-698, 2003
115. Spitz MR, Hsu TC, Wu X, et al: Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 4:99-103, 1995
116. Wei Q, Cheng L, Amos CI, et al: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A molecular epidemiologic study. J Natl Cancer Inst 92:1764-1772, 2000
117. Zheng YL, Loffredo CA: Bleomycin-induced chromosome breaks as a risk marker for lung cancer: A case-control study with population and hospital controls. Carcinogenensis 24: 269-274, 2003
118. Misra RR, Ratnasinghe D, Tangrea JA, et al: Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett 191:171-178, 2003
119. Wu X, Zhao H, Wei Q, et al: XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. Carcinogenesis 24:505-509, 2003
120. Gao WM, Romkes M, Day RD, et al: Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Carcinogenesis 24:1671-1676, 2003
121. Liang G, Xing D, Miao X, et al: Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer 105:669-673, 2003
122. World Health Organization: International Agency for Research on Cancer (IARC): World Cancer Report. Lyon, France, IARC Press, 2003
123. Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349: 1436-1442, 1997
124. Peto R, Chen ZM, Boreham J: Tobacco-The growing epidemic. Nat Med 5:15-17, 1999
125. Liu BQ, Peto R, Chen Z-M, et al: Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ 317:1411-1422, 1998